dc.contributor.author |
Yuste Mateos, Víctor J. (Víctor José) |
dc.contributor.author |
Sánchez-López, Isabel |
dc.contributor.author |
Solé Serra, Carme |
dc.contributor.author |
Encinas Martín, Mario |
dc.contributor.author |
Bayascas Ramírez, José Ramón |
dc.contributor.author |
Boix Torras, Jacint |
dc.contributor.author |
Comella i Carnicé, Joan Xavier |
dc.date |
2016-05-12T08:29:02Z |
dc.date |
2002 |
dc.date |
10000-01-01 |
dc.identifier |
0022-3042 |
dc.identifier |
http://hdl.handle.net/10459.1/57017 |
dc.identifier |
https://doi.org/10.1046/j.0022-3042.2001.00695.x |
dc.identifier.uri |
http://hdl.handle.net/10459.1/57017 |
dc.description |
Staurosporine is one of the best apoptotic inducers in different cell types including neuroblastomas. In this study we have compared the efficiency and final outcome of three different anti-apoptotic strategies in staurosporine-treated SH-SY5Y human neuroblastoma cells. At staurosporine concentrations up to 500 nm, z-VAD.fmk a broad-spectrum, noncompetitive inhibitor of caspases, reduced apoptosis in SH-SY5Y cells. At higher concentrations, z-VAD.fmk continued to inhibit caspases and the apoptotic phenotype but not cell death which seems to result from oxidative damage. Stable over-expression of Bcl-2 in SH-SY5Y protected cells from death at doses of staurosporine up to 1 microm. At higher doses, cytochrome c release from mitochondria occurred, caspases were activated and cells died by apoptosis. Therefore, we conclude that Bcl-2 increased the threshold for apoptotic cell death commitment. Over-expression of Bcl-X(L) was far more effective than Bcl-2. Bcl-X(L) transfected cells showed a remarkable resistance staurosporine-induced cytochrome c release and associated apoptotic changes and survived for up to 15 days in 1 microm staurosporine. In these conditions, SH-SY5Y displayed a remarkable phenotype of neuronal differentiation as assessed by neurite outgrowth and expression of neurofilament, Tau and MAP-2 neuronal specific proteins. |
dc.description |
This work was founded by Spanish Govern Comisión Interministerial de Ciencia y Tecnología through the Plan Nacional de Salud y Farmacia (contract numbers SAF2000-0164-C02-01 and 1FD97-0514-02-01) and Ajuntament de Lleida. VJY is a predoctoral fellow supported by the European Union contracts BIO4-CT96-0433 and QLG3-CT-1999-00602. JRB was supported by grant 1FD97-0514- C02-01 from Spanish Ministry of Science and Technology. |
dc.language |
eng |
dc.publisher |
Wiley |
dc.relation |
MICYT/PN2000-2003/SAF2000-0164-C02-01 |
dc.relation |
Reproducció del document publicat a https://doi.org/10.1046/j.0022-3042.2001.00695.x |
dc.relation |
Journal of Neurochemistry, 2002, vol. 80, núm. 1, p. 126-139 |
dc.rights |
(c) International Society for Neurochemistry, 2002 |
dc.rights |
info:eu-repo/semantics/restrictedAccess |
dc.subject |
Bcl-2 |
dc.subject |
Bcl-XL |
dc.subject |
Neuritogenesis |
dc.subject |
SH-SY5Y cells |
dc.title |
The prevention of the staurosporine-induced apoptosis by Bcl-XL, but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells |
dc.type |
article |
dc.type |
publishedVersion |